BEIJING and SHANGHAI, April 28, 2019 /PRNewswire/ -- Sinovant Sciences today announced that its Clinical Trial Application (CTA) for derazantinib has been accepted by the Center for Drug Evaluation at the China National Medical Products Administration (NMPA), enabling the initiation of a...
from PR Newswire: https://prn.to/2PzvtZ9
No comments:
Post a Comment